CUFinder

Jiachen Yang

About Jiachen Yang

Jiachen Yang, With an exceptional h-index of 39 and a recent h-index of 28 (since 2020), a distinguished researcher at Osaka University, specializes in the field of Software Engineering.

His recent articles reflect a diverse array of research interests and contributions to the field:

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+ …

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)

30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC

PL03. 13 osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2)

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer …

Jiachen Yang Information

University

Position

PhD Student

Citations(all)

9364

Citations(since 2020)

4311

Cited By

3811

hIndex(all)

39

hIndex(since 2020)

28

i10Index(all)

144

i10Index(since 2020)

64

Email

University Profile Page

Google Scholar

Jiachen Yang Skills & Research Interests

Software Engineering

Top articles of Jiachen Yang

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Journal of Clinical Oncology

2024/4

Goran Stojanovic
Goran Stojanovic

H-Index: 15

Patricia Rich
Patricia Rich

H-Index: 5

Li Zhang
Li Zhang

H-Index: 7

38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+ …

ESMO Open

2024/3/1

Y Wu
Y Wu

H-Index: 5

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

ESMO open

2023/4/1

161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)

Journal of Thoracic Oncology

2023/4/1

30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC

Journal of Thoracic Oncology

2023/4/1

PL03. 13 osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2)

Journal of Thoracic Oncology

2023/11/1

Ck Lee
Ck Lee

H-Index: 10

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of Oncology

2023/11/1

510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer …

Annals of Oncology

2023/11/1

OA21. 06 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial

Journal of Thoracic Oncology

2023/11/1

M Thomas
M Thomas

H-Index: 8

P2. 11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

Journal of Thoracic Oncology

2023/11/1

LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

Annals of Oncology

2023/10/1

Effect of Dose to the Heart and Cardiac Substructures on Cardiac Toxicity after Breast Cancer Radiation

International Journal of Radiation Oncology, Biology, Physics

2023/10/1

Impact of Stomach Deformability on PTV Coverage in Patients with Gastric MALTs Treated with Deep Inspiration Breath Hold (DIBH) and Daily CT-based Image-guided Radiation …

International Journal of Radiation Oncology, Biology, Physics

2023/10/1

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

Annals of Oncology

2023/10/1

PCR105 Patient Risk-Benefit Preferences for Transcatheter Versus Surgical Mitral Valve Repair

Value in Health

2023/6/1

PCR106 Comparing Maximum-Acceptable Risk Estimates from 2 Preference-Elicitation Methods: A Discrete-Choice Experiment and a Threshold-Technique Exercise

Value in Health

2023/6/1

PCR40 Waiting for a Good Kidney: Do Patients Think It’s Worth It?

Value in Health

2023/6/1

Ch Wu
Ch Wu

H-Index: 8

EP08. 02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+ osimertinib in EGFRm NSCLC post-osimertinib

Journal of Thoracic Oncology

2022/9/1

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cancer discovery

2022/7/6

Mengzhao Wang
Mengzhao Wang

H-Index: 0

Jian Fang
Jian Fang

H-Index: 1

Jianying Zhou
Jianying Zhou

H-Index: 33

Yun Fan
Yun Fan

H-Index: 3

Ying Cheng
Ying Cheng

H-Index: 23

Bo Gao
Bo Gao

H-Index: 10

Yan Xu
Yan Xu

H-Index: 10

Li Zheng
Li Zheng

H-Index: 8

PCR54 Patient Preferences for Treatment Alternatives for Drug-Resistant Epilepsy

Value in Health

2022/7/1

S Sinha
S Sinha

H-Index: 4

See List of Professors in Jiachen Yang University(Osaka University)